This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cervical cancer	Dual specificity phosphatase 3 (DUSP3; VHR)	*In vitro* studies identified inhibitors of VHR that could help treat cervical cancer. A high throughput screen and SAR analysis identified inhibitors that bound to the active site of VHR. *In vitro*, the inhibitors prevented proliferation of cervical cancer cells without affecting growth of normal keratinocytes. Next steps include determining the pharmacokinetic and toxicity profiles of the compounds in mice and then determining the effect of the compounds on cancer development in human papillomavirus 16 transgenic mice. *SciBX* **2**(39); doi:10.1038/scibx.2009.1468 Published online Oct. 8, 2009	Anticancer compounds patented; available for licensing from the Burnham Institute for Medical Research **Contact:** Carol Lynn Curchoe, Burnham Institute for Medical Research, La Jolla, Calif. e-mail: ccurchoe@burnham.org	Wu, S. *et al. J. Med. Chem.*; published online Sept. 25, 2009; doi:10.1021/jm901016k **Contact:** Lutz Tautz, Burnham Institute for Medical Research, La Jolla, Calif. e-mail: tautz@burnham.org